The Effect Of Metformin And Atorvastatin Combination In The Treatment Of Diabetes Complicated With Hyperlipidemia

Diabetes mellitus is a series ofmetabolic diseases caused by absolute insulin deficiency or low insulin action,and hyperglycemia is the most typical symptom. Insulin regulates human protein,fat and blood sugar metabolism at the same time, and the disorder of insulinregulation in diabetic patients can easily lead to other complications such aslipid metabolism disorder in patients. Statistics show that more than 50% ofdiabetic patients are combined with different degrees of hyperlipidemia, andthe incidence of hyperlipidemia will further increase due to improper controlof blood sugar in patients. Diabetes is a glucose metabolic disease caused by avariety of factors. In recent years, with the change of people's lifestyle anddiet structure and the aging trend of the population becoming more obvious, theincidence of diabetes is increasing year by year, and it has become a groupchronic disease that seriously threatens the health of middle-aged and elderlygroups. Metformin and atorvastatin combination in the treatment of diabetesmellitus with hyperlipidemia is also more urgent.

Due to diabetic hyperlipemia canbring more and more serious harm to people with diabetes, increased in patientswith coronary heart disease, stroke, diabetes, kidney disease or other risk oflong-term complications, affecting long-term survival in patients with qualityand lead to further deterioration, and may even cause sudden severe disease ofheart head blood-vessel, shorten the survival time of patients, so researchersare speeding up studies of metformin and atorvastatin combination. It is ofgreat significance to improve the effectiveness of blood sugar control anddelay the progression of the disease in patients with diabetes andhyperlipidemia. There are two types of hyperlipidemia: primary and secondary.Primary hyperlipidemia is mainly related to genetic factors. Patients withsingle gene defects and polygenic defects may lead to protein transport,metabolic receptors, enzymes and load cells in the body. Abnormal lipoproteins,in addition to genetic factors, diet, nutrition, and drugs may also cause thedisease through unknown mechanisms. Secondary hyperlipidemia is generallysecondary to metabolic disorders, and gender, age, season, bad living habits,mental and emotional stress may all cause the disease.

The main clinical manifestations ofhyperlipidemia are xanthoma caused by subdermal deposition of lipids andarteriosclerosis caused by lipid deposition in vascular endothelium. Theoverall incidence of xanthomas caused by hyperlipidemia is not high, and theprogression of atherosclerosis is slow. Therefore, hyperlipidemia generally hasno obvious symptoms and signs, and abnormal plasma lipoprotein levels areusually found accidentally during other blood biochemical tests. Diabetesmellitus with hyperlipidemia is a disorder of lipid metabolism caused byinsulin resistance and insufficient insulin secretion. Free fatty acidsgradually form high concentrations of TG and attach to the arterial wall of thebody, resulting in a significant increase in the thickness of the blood vesselwall and stenosis of the lumen, affecting the blood supply to the organs. Type2 diabetes mellitus patients have complex types of lipid metabolism disorders,among which the mixed type is the most common, mainly manifested as abnormallyelevated serum lipid levels, and lipid metabolism disorders can acceleratearterial atherosclerosis and induce microvascular complications. Fatty acidsalso affect the utilization of glucose by muscles. Some researchers haveproposed the concept of glucose-fatty acid cycle. They believe that there is ametabolic competition between glucose and fatty acids, and there is a closerelationship between glucose metabolism and lipid metabolism. Type 2 diabetesis even called for glycolipidosis, clinical treatment should also start fromboth hypoglycemic and lipid lowering.

Metformin is the first choice forthe treatment of type 2 diabetes mellitus for which simple diet control andphysical exercise have no significant effect, especially for obese type 2diabetes mellitus. Metformin combined with insulin in the treatment of diabetescan effectively reduce insulin dosage and reduce the risk of hypoglycemia, andit can also play a synergistic effect with sulfonylurea drugs. Metformin is abiguanide drug that can effectively increase the number of insulin receptors inperipheral tissues, thereby significantly improving the uptake rate of bloodglucose by peripheral tissues and improving insulin resistance in the body.Metformin can also effectively control the appetite of patients, help patientscontrol their diet, and improve the effectiveness of dietary interventions inpatients. Atorvastatin is a common clinical lipid-lowering drug. It is widelyused in the treatment of hypercholesterolemia, coronary heart disease, andcritically ill coronary heart disease. It can effectively reduce the risk ofnon-fatal myocardial infarction, stroke, and heart failure. Atorvastatin has 20years of clinical application experience and is being clinically used in morethan 130 countries. The therapeutic effect and safety of 230 million patientsper year have been formally used clinically. Atorvastatin can effectivelyreduce the level of low-density lipoprotein cholesterol and reducecardiovascular disease. Incident probability, clinical drug safety is alsohigh. Studies have shown that metformin and atorvastatin combination is moreeffective in the treatment of diabetes and hyperlipidemia than that ofmetformin alone, indicating that hypoglycemic combined with lipid-loweringtherapy can enhance the efficacy of the drug and achieve better therapeuticeffects.

To sum up, the clinical effect ofmetformin and atorvastatin combination in the treatment of diabetes mellituswith hyperlipidemia is significant, and it has high clinical application andpromotion value.